Sonoco ThermoSafe acquires AAR cold chain solutions assets

6 九月, 21:34
Sonoco ThermoSafe has acquired the PharmaPort 360™ assets, licenses, trademarks and manufacturing rights from AAR, to enter the active temperature-controlled cargo containers market, as the company said in the press release received by Lesprom Network.

Sonoco ThermoSafe will own and lease the PharmaPort 360 containers globally while signing a multi-year agreement with AAR to manufacture, repair and perform maintenance services. The PharmaPort 360 is an innovative active container that uses regenerative heat exchangers to maintain stringent temperature control for high-value cargo.

These containers, which are approved by the U.S. Federal Aviation Authority (FAA), can be used to safely ship temperature-sensitive pharmaceuticals, blood plasma and other biological cargo via air or ground transportation.

Vicki Arthur, vice president of Sonoco Protective Solutions, said, “This acquisition is in line with our strategy to provide the best temperature-controlled shipping solution irrespective of technology platform (passive or active) to meet our customers’ critical needs for shipping high-value pharmaceuticals and biologics globally. Sonoco is committed to investing in passive and active technologies, like that of PharmaPort 360, and expanding its presence globally in the temperature-controlled packaging industry.”

PharmaPort® containers provide safe, reliable 5°C door-to-door transport of pharmaceuticals and other high-value cargo. Its exclusive Pro-Tectic® regenerative phase change technology uses active cooling and heating to maintain assured product temperature stability through an ambient temperature range of -40°C to +60°C.

Sonoco ThermoSafe is a leading global provider of temperature assurance packaging for the safe and efficient transport of pharmaceuticals, biologics, vaccines and other temperature-sensitive products.


標籤: Sonoco

評論

喜歡這一點,你需要註冊。
要做到這一點,請輸入您的姓名和電子郵件地址。
名稱:
姓:
電子郵件:
性別:
如果您已經註冊,
請輸入您的詳細信息 這裡
要留下意見,你需要註冊。
要做到這一點,請輸入您的姓名和電子郵件地址。
名稱:
姓:
電子郵件:
性別:
如果您已經註冊,
請輸入您的詳細信息 這裡
我們歡迎通過相關的意見和數據推動故事的評論。如果你看到一個評論,您認為是無關緊要的或不適當的,可以將其標記為我們的編輯使用報告濫用鏈接。在表達意見的看法,並不代表Lesprom網絡。有關我們註釋策略的更多信息,請參見: http://www.lesprom.com/legal/comment_policy/
返回頁首